UC Disease Overview & Classifications
Treatment Options for Advanced or Metastatic UC
First-Line Treatments
Maintenance and Second-Line Options
Emerging Treatments
Managing, Monitoring, Mitigating & Adverse Events
Question & Answer Session/Closing Remarks
Elizabeth R. Plimack, MD, MS
Chief, Division of Genitourinary Medical Oncology
Professor, Department of Hematology/Oncology
Director, Genitourinary Clinical Research
Fox Chase Cancer Center
Temple University Health System
Philadelphia, Pennsylvania
Susan K. Roethke, CRNP, MSN, ANP-BC, AOCNP
Advanced Practice Clinician
Certified Registered Nurse Practitioner
Fox Chase Cancer Center
Philadelphia, Pennsylvania
When diagnosed in advanced or metastatic stages, urothelial carcinoma (UC), the histopathologic foundation for ≥90% of all urinary bladder cancer (UBC) cases, a heavily cytotoxic “sledgehammer” approach has traditionally been used. This involves systemic platinum-based chemotherapy regimens for UC that has morphed into muscle-invasive bladder cancer (MBIC). Until recently, there were no second-line options beyond the chemotherapeutic sledgehammer. In 2020, patients with MBIC or advanced or metastatic UC (mUC) in other urinary organs (eg, renal pelvis and ureters) are finding that bacillus Calmette-Guérin (BCG) presaged more selective, targeted treatments. These new and emerging treatments take advantage of recently unraveled translational insights into UC. Five immune checkpoint inhibitors (ICIs) were approved between 2016 and 2017 for first- or second-line treatment of UC in the adjuvant or neoadjuvant settings. Two treatments with completely different mechanisms of action (MOA) — a fibroblast growth factor receptor (FGFR) inhibitor and an antibody drug conjugate (ADC) — were granted accelerated approval for advanced or mUC in 2019. For clinicians who manage patients with advanced or mUC, these treatments offer cytotoxic potency with more selectively targeted MOAs for patients who have run out of treatment options. But for clinicians, the introduction of these agents and others still in development complicate an already complex condition. This activity will help advanced practitioners who treat patients with UC to know how to select and sequence these treatments as well as how to identify and manage potential treatment-related adverse events (trAEs).
This educational initiative has been designed for advanced practice providers caring for patients with urothelial carcinoma including nurse practitioners (NPs), physician assistants (PAs), clinical nurse specialists (CNSs), advanced practice nurses (APNs), oncology clinical nurses (OCNs) and clinical oncology pharmacists (BCOPs).
Upon completion of this educational activity, participants should be able to:
Articulate the mechanisms of action of targeted biopharmacologics and immune checkpoint inhibitors (ICIs) used in the treatment of urothelial cancer (UC)
Outline efficacy and safety findings from key clinical trials of approved and investigational ICIs, antibody-drug conjugates (ADCs), and fibroblast growth factor receptor (FGFR) inhibitors developed for the treatment of advanced or metastatic UC
Implement a patient-focused strategy for identifying, monitoring, and mitigating adverse events that can be caused by novel UC treatments
Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Integrity Continuing Education, Inc. designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.
This educational activity for 1.25 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Global Education Group and Integrity Continuing Education. Global Education Group is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 110121. This activity is approved for 1.25 contact hour(s) (which includes *hour(s) of pharmacology).
*Pharmacology hours are TBD after clinical content review.
Integrity Continuing Education and Global Education Group requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. A full list of disclosure information for faculty will be provided during the conference.
A detailed disclosure for all persons in control of content, including faculty presenters, will be provided at the live event.
The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Novartis Pharmaceuticals Corporation do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
In order to receive credit for this activity, the participant must complete the pretest, posttest, and complete the evaluation form. A statement of credit will be issued only upon receipt of a completed activity evaluation form.
There is no fee for this online live educational activity.
Windows 98, 2000, XP, 2003, Vista, and 7
Internet Explorer 6/7
Firefox 2
Mozilla 1.7 or higher
Netscape 8.1 or higher
Flash Player 10
Mac OS X 10.3, 10.4
Safari 1.3 (Mac OS 10.3)
Safari 2.0 or higher (Mac OS 10.4)
Firefox 2
Flash Player 10
Use of Internet Explorer browser is not recommended.
Click here for more information on minimum system requirements.
For information about the accreditation (ANCC & AANP) of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.
For information about the accreditation (ACCME) of this program, please contact Integrity CE at 1-855-835-4004 or information@integrityce.com.
This CME activity is provided by Integrity Continuing Education.
This CE activity is jointly provided by Global Education Group and Integrity Continuing Education.
This activity is supported by educational grants from Astellas, Merck Sharp & Dohme, and Seattle Genetics.
UC Disease Overview & Classifications
Treatment Options for Advanced or Metastatic UC
First-Line Treatments
Maintenance and Second-Line Options
Emerging Treatments
Managing, Monitoring, Mitigating & Adverse Events
Question & Answer Session/Closing Remarks